References
- Bellinvia S, Edwards CJ. Explaining biosimilars and how reverse engineering plays a critical role in their development. Expert Opin Drug Discov. 2020;15(11):1283–1289. PubMed PMID: 32717155. doi: 10.1080/17460441.2020.1796627
- Schiestl M, Zabransky M, Sörgel F. Ten Years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Devel Ther. 11 PubMed PMID: 28553082 2017 May 16: 1509–1515. doi: 10.2147/DDDT.S130318
- Medicare Part B Drug Average Sales Price, Center for Medicare and Medicaid Services; 2023. [cited 2023 Mar 22]. Available from: https://www.cms.gov/medicare/medicare-fee-for-service-part-b-drugs/mcrpartbdrugavgsalesprice.
- Niazi SK. The coming of age of biosimilars: a personal perspective. Biologics. 2022;2(2):107–127. doi: 10.3390/biologics2020009
- Chen Y, Monnard A, da Silva JS An Inflection Point for Biosimilars; 2021. [cited 2023 Mar 22] Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/an-inflection-point-for-biosimilars
- McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2017;20(10):1083–1093. PubMed PMID: 28722494. doi: 10.1080/13696998.2017.1358173
- McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–2295. PubMed PMID: 28870106. doi: 10.2217/fon-2017-0374
- McBride A, Campbell K, Bikkina M, et al. Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2018;21(6):606–609. PubMed PMID: 28722494. doi: 10.1080/13696998.2018.1452749
- McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. J Med Econ. 2020;23(1):28–36. PubMed PMID: 31433700. doi: 10.1080/13696998.2019.1658591
- McBride A, Wang W, Campbell K, et al. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. J Med Econ. 2020;23(8):856–863. PubMed PMID: 32323582. doi: 10.1080/13696998.2020.1760284
- MacDonald K, McBride A, Alrawashdh N, et al. Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv. J Med Econ. 2020;23(12):1466–1476. PubMed PMID: 33023360. doi: 10.1080/13696998.2020.1833339
- McBride A, MacDonald K, Abraham I. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma. Leuk Res. 2021;106:106591. PubMed PMID: 33957339. doi: 10.1016/j.leukres.2021.106591
- McBride A, MacDonald K, Fuentes-Alburo A, et al. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer. J Med Econ. 2021;24(1):743–756. PubMed PMID: 34003067. doi: 10.1080/13696998.2021.1928515
- MacDonald K, Alrawashdh N, McBride A, et al. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Future Oncol. 2021;17(33):4561–4570. PubMed PMID: 34382416. doi: 10.2217/fon-2021-0718
- Biosimilars in the U.S. 2020–2024. 2020 [cited 2023 Mar 22]. Available from. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024
- President signs into law bipartisan legislation introduced by senators cassidy, hassan to lower health care costs by improving education about drug products; 2021. [cited 2023 Mar 22]. Available from: https://www.cassidy.senate.gov/newsroom/press-releases/president-signs-into-law-bipartisan-legislation-introduced-by-senators-cassidy-hassan-to-lower-health-care-costs-by-improving-education-about-drug-products
- The World Bank. New world bank country classifications by income level: 2022-2023; 2023. [cited 2023 Mar 22]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
- IQVIA. Realizing biosimilar potential in the middle east & Africa; 2020. [cited 2023 Mar 22]. Available from: https://www.iqvia.com/locations/middle-east-and-africa/library/white-papers/realizing-biosimilar-potential-in-the-middle-east-and-africa
- Jordan Food & Drug Administration; 2023. [cited 2023 Mar 22]. Available from: http://www.jfda.jo/
- Pi Pharma Intelligence. LLC; 2023. [cited 2023 Mar 22]. Available at a fee: https://www.pipharmaintelligence.com/pi-insight
- Niazi SK. Contributor: FDA Introduces New AI-Based Safety Evaluation Tool to Help Demonstrate Biosimilarity; 2023. [cited 2023 Mar 22]. Available from: https://www.centerforbiosimilars.com/view/contributor-fda-introduces-new-ai-based-safety-evaluation-tool-to-help-demonstrate-biosimilarity
- Batran RA, Elmoshneb M, Hussein AS, et al. Biosimilars: science, implications, and potential outlooks in the middle east and Africa. Biologics [ PubMed PMID: 36225324]. 2022;16:161–171. doi: 10.2147/BTT.S376959
- Abraham I It’s what we do with the savings: economics and equity. Center for Biosimilars; 2022. [cited 2022 Oct 27]. Available from: https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-it-s-what-we-do-with-the-savings-economics-and-equity
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting: δ3: reference-based pricing [published correction appears in J Med Econ. 2020 Sep 29: 1-6. J Med Econ. 2020;23(11):1230–1236. PubMed PMID: 32845191. doi: 10.1080/13696998.2020.1815027
- Choi BM, Abraham RB, Halawah H, et al. Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. J Med Econ. 2021;24(sup1):34–41. PubMed PMID: 34866529. doi: 10.1080/13696998.2021.2007705